To include your compound in the COVID-19 Resource Center, submit it here.

BC-3781: Phase II data

Data from 165 clinically evaluable patients in a double-blind, U.S. Phase II trial showed that twice-daily 100 and 150 mg IV BC-3781 produced

Read the full 238 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE